A cost‐effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0223|35|5|440-446

ISSN： 0197-3851

Source： PRENATAL DIAGNOSIS, Vol.35, Iss.5, 2015-05, pp. : 440-446

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: high detection with low rates of invasive procedures

By  

PRENATAL DIAGNOSIS, Vol. 35, Iss. 8, 2015-08 ,pp. : 789-796

John Wiley & Sons Inc

Access to resources Recommend Favorite

OP08.04: Non‐invasive prenatal testing (NIPT) to screen Down's syndrome in France: a cost‐effectiveness analysis

By  

ULTRASOUND IN OBSTETRICS & GYNECOLOGY, Vol. 48, Iss. S1, 2016-09 ,pp. : 76-76

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-effectiveness of Colorectal Cancer Screening

By Lansdorp-Vogelaar Iris   Knudsen Amy B.   Brenner Hermann  

Epidemiologic Reviews, Vol. 33, Iss. 1, 2011-05 ,pp. : 88-100

Oxford University Press

Access to resources Recommend Favorite

Reflex antenatal DNA screening for Down syndrome

By  

PRENATAL DIAGNOSIS, Vol. 35, Iss. 11, 2015-11 ,pp. : 1154-1154

John Wiley & Sons Inc

Access to resources Recommend Favorite

A French approach to cost-effectiveness analysis?

By Pouvourville Gérard  

The European Journal of Health Economics, Vol. 11, Iss. 6, 2010-12 ,pp. : 521-523

Springer Publishing Company

Access to resources Recommend Favorite